Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.

Matias TrilliniAnna CaroliNorberto PericoAndrea RemuzziPaolo BrambillaGiulia VillaAnnalisa PernaTobia PeracchiNadia RubisDavide MartinettiMariarosa CarusoValentina Fanny LeoneDaniela CuginiFabiola CarraraGiuseppe RemuzziPiero Ruggenentinull null

Published in: Clinical journal of the American Society of Nephrology : CJASN (2023)

Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL), NCT03541447.

Keyphrases

polycystic kidney disease
placebo controlled
phase iii
study protocol
double blind
phase ii
neuroendocrine tumors
clinical trial
open label
randomized controlled trial
phase ii study
radiation therapy
atrial fibrillation